Cenexi operational turnaround delays
Cenexi faces operational issues including lower productivity, old lines, and regulatory hurdles for product line shifts, which may delay margin recovery.
high · management_commentaryGland Pharma Limited — Q3 FY24
Gland Pharma reported consolidated revenue of INR 1,545 crore in Q3 FY24, up 65% YoY, driven by the Cenexi acquisition and strong US base business growth of 17% YoY.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Cenexi revenue growth may be pushed out
Analyst question highlighted that operational issues could delay the EUR 30-40 million incremental revenue from new programs beyond FY2026.
medium · analyst_questionIndia business decline
India revenue declined 7% YoY and remains a low-focus market, with limited growth visibility due to DPCO pricing pressures.
low · data_observation